TANGO THERAPEUTICS, INC.
TNGXLoading price...
Overview
Previous Close12.35
Open12.20
Ask16.98
Bid16.74
Day's Range11.80 - 16.97
52 Week Range1.03 - 16.97
PE Ratio(TTM)--
Market Cap2.27B
Volume17.92M
Avg. Volume2.91M
12 Months Earnings-100.52M
12 Months Revenue66.50M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Revenue | 66.50M | 24.30M | 42.07M | 36.53M | 24.86M | 37.04M |
| Operating Expenses | 176.84M | 181.58M | 187.66M | 150.70M | 135.93M | 95.23M |
| Profit after Tax (Net Income) | -100.52M | -145.57M | -130.30M | -101.74M | -108.18M | -58.23M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Boston, United States
Website: https://www.tangotx.com
Founder & Executive Chair: Dr. Barbara L. Weber M.D.
Employees: 155
About Company:
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.